United States: Amneal Expands Oncology Offering With Two Denosumab Biosimilars - Goodwin Procter LLP
On October 12, Amneal announced that it will be adding two denosumab biosimilars to its oncology pipeline, referencing PROLIA and XGEVA.
Full Article